Skip to main content

MSTPublications: February 2022

Posted by on Friday, February 25, 2022 in New Publications .

Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension.
Wu P, Feng Q, Kerchberger VE, Nelson SD, Chen Q, Li B, Edwards TL, Cox NJ, Phillips EJ, Stein CM, Roden DM, Denny JC, Wei WQ.
Nat Commun. 2022 Jan 10;13(1):46. doi: 10.1038/s41467-021-27751-1.

Discovering novel uses for existing drugs, through drug repurposing, can reduce the time, costs, and risk of failure associated with new drug development. However, prioritizing drug repurposing candidates for downstream studies remains challenging. Here, we present a high-throughput approach to identify and validate drug repurposing candidates. This approach integrates human gene expression, drug perturbation, and clinical data from publicly available resources. We apply this approach to find drug repurposing candidates for two diseases, hyperlipidemia and hypertension. We screen >21,000 compounds and replicate ten approved drugs. We also identify 25 (seven for hyperlipidemia, eighteen for hypertension) drugs approved for other indications with therapeutic effects on clinically relevant biomarkers. For five of these drugs, the therapeutic effects are replicated in the All of Us Research Program database. We anticipate our approach will enable researchers to integrate multiple publicly available datasets to identify high priority drug repurposing opportunities for human diseases.

NOTCH1 PEST domain variants are responsive to standard of care treatments despite distinct transformative properties in a breast cancer model.
Cravero K, Pantone MV, Shin DH, Bergman R, Cochran R, Chu D, Zabransky DJ, Karthikeyan S, Waters IG, Hunter N, Rosen DM, Kyker-Snowman K, Dalton WB, Button B, Shinn D, Wong HY, Donaldson J, Hurley PJ, Croessmann S, Park BH.
Oncotarget. 2022 Feb 16;13:373-386. doi: 10.18632/oncotarget.28200. eCollection 2022.

Learning white matter subject-specific segmentation from structural MRI.
Yang Q, Hansen CB, Cai LY, Rheault F, Lee HH, Bao S, Chandio BQ, Williams O, Resnick SM, Garyfallidis E, Anderson AW, Descoteaux M, Schilling KG, Landman BA.
Med Phys. 2022 Jan 28. doi: 10.1002/mp.15495. Online ahead of print.

Characterization of resting functional MRI activity alterations across epileptic foci and networks.
Sainburg LE, Little AA, Johnson GW, Janson AP, Levine KK, González HFJ, Rogers BP, Chang C, Englot DJ, Morgan VL.
Cereb Cortex. 2022 Feb 12:bhac035. doi: 10.1093/cercor/bhac035. Online ahead of print.

Expressing the Human Cholesteryl Ester Transfer Protein Minigene Improves Diet-Induced Fatty Liver and Insulin Resistance in Female Mice.
Zhu L, An J, Chinnarasu S, Luu T, Pettway YD, Fahey K, Litts B, Kim HH, Flynn CR, Linton MF, Stafford JM.
Front Physiol. 2022 Jan 10;12:799096. doi: 10.3389/fphys.2021.799096. eCollection 2021.

Increased amplitude of hippocampal low frequency fluctuations in early psychosis: A two-year follow-up study.
McHugo M, Rogers BP, Avery SN, Armstrong K, Blackford JU, Vandekar SN, Roeske MJ, Woodward ND, Heckers S.
Schizophr Res. 2022 Feb 15;241:260-266. doi: 10.1016/j.schres.2022.02.003. Online ahead of print.

Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer.
Elkrief A, Wu JT, Jani C, Enriquez KT, Glover M, Shah MR, Shaikh HG, Beeghly-Fadiel A, French B, Jhawar SR, Johnson DB, McKay RR, Rivera DR, Reuben DY, Shah S, Tinianov SL, Vinh DC, Mishra S, Warner JL.
Cancer Discov. 2022 Feb;12(2):303-330. doi: 10.1158/2159-8290.CD-21-1368. Epub 2021 Dec 10.
PMID: 34893494 Review.

Innate Immune Memory and the Host Response to Infection.
Sherwood ER, Burelbach KR, McBride MA, Stothers CL, Owen AM, Hernandez A, Patil NK, Williams DL, Bohannon JK.
J Immunol. 2022 Feb 15;208(4):785-792. doi: 10.4049/jimmunol.2101058.
PMID: 35115374 Review.